The information in this section is intended for visitors outside the United States.
Chronic infection with the hepatitis B or C virus can lead to serious and life-threatening liver damage, including liver cirrhosis (scarring), cancer and the need for liver transplantation. More than 500 million people worldwide live with chronic hepatitis B or C, making the infections many times more common than HIV.
Viread® (tenofovir disoproxil fumarate) is indicated for the treatment of chronic hepatitis B. We work with regional business partners and generic licensing partners to sell Viread for HBV at discounted prices in more than 125 developing countries - the same countries in which Viread is available for HIV. We are working to increase the number of access countries in which Viread is registered for HBV. HCV is also a key therapeutic focus area for Gilead. We have an active research and development program evaluating a number of antiviral combinations and treatment durations in different patient populations. As Gilead HCV medicines advance through the research and development pipeline, we will evaluate opportunities to incorporate them into our access programs.
See a country-by-country list of Viread hepatitis B registrations: